See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: In this retrospective study, we evaluated the biochemical recurrence rate, metastatic disease progression, and prostate cancer-specific and overall survival in patients curatively treated with external beam radiotherapy (EBRT) for early prostate cancer (PC). We also examined the prognostic effect of comorbidity by Charlson Comorbidity Index (CCI) and overall performance status by Eastern Clinical Oncology Group (ECOG) score. Methods: A total of 665 men treated between 2008 and 2013 were enrolled from Tampere University Hospital, Finland. Prostate-specific antigen (PSA) tests and hospital records were used to determine the 5-year survival for each aforementioned endpoint using a Kaplan-Meyer estimate. To analyze the impact of the selected prognostic factor, we used a Cox regression model to calculate the corresponding hazard ratio (HR) and 95 % confidence interval (CI). Results: With a median follow-up-time of 7.12 years, the 5-year overall survival (OS) after EBRT was 88.9 % [86.5 %-91.3 %], prostate cancer-specific survival (PCSS) was 97.9 % [96.7 %-99.1%], metastasis-free survival (MFS) 94.8 % [93.0 %-96.6 %] and biochemical recurrence-free survival (BRFS) 88.7 % [86.2 %-91.2 %]. Both CCI (HR = 1.38, [1.25-1.51]) and ECOG score (HR = 1.63, [1.29-2.05]) declined OS, as well as Gleason score and T score (P < 0.05). Gleason score and T grade also associated to worse PCSS, MFS and BRFS. Conclusions: CCI and ECOG score are useful tools in evaluating the overall life expectancy of the patient after EBRT for PC. T-stage and Gleason score remain still the major prognostic factors.
Keywords
Prostate Cancer, Radiotherapy, Treatment Outcome, Comorbidity, Physical Fitness
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 31 Mar, 2020
Editorial decision: Accept
On 31 Mar, 2020
Version 2
Posted 16 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 20 Mar, 2020
Reviewers invited
Invitations sent on 11 Mar, 2020
Editor assigned
On 09 Mar, 2020
Submission checks complete
On 08 Mar, 2020
Editor invited
On 08 Mar, 2020
No comments provided
Editorial decision: Major revision
On 25 Feb, 2020
Review #3 received
Received 17 Feb, 2020
Reviewer #3 agreed
On 13 Feb, 2020
Review #2 received
Received 05 Feb, 2020
Reviewer #2 agreed
On 22 Jan, 2020
Review #1 received
Received 18 Jan, 2020
Reviewers invited
Invitations sent on 15 Jan, 2020
Reviewer #1 agreed
On 15 Jan, 2020
Editor assigned
On 14 Jan, 2020
Submission checks complete
On 11 Dec, 2019
Editor invited
On 10 Dec, 2019
First submitted
On 06 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 31 Mar, 2020
Editorial decision: Accept
On 31 Mar, 2020
Version 2
Posted 16 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 20 Mar, 2020
Reviewers invited
Invitations sent on 11 Mar, 2020
Editor assigned
On 09 Mar, 2020
Submission checks complete
On 08 Mar, 2020
Editor invited
On 08 Mar, 2020
No comments provided
Editorial decision: Major revision
On 25 Feb, 2020
Review #3 received
Received 17 Feb, 2020
Reviewer #3 agreed
On 13 Feb, 2020
Review #2 received
Received 05 Feb, 2020
Reviewer #2 agreed
On 22 Jan, 2020
Review #1 received
Received 18 Jan, 2020
Reviewers invited
Invitations sent on 15 Jan, 2020
Reviewer #1 agreed
On 15 Jan, 2020
Editor assigned
On 14 Jan, 2020
Submission checks complete
On 11 Dec, 2019
Editor invited
On 10 Dec, 2019
First submitted
On 06 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: In this retrospective study, we evaluated the biochemical recurrence rate, metastatic disease progression, and prostate cancer-specific and overall survival in patients curatively treated with external beam radiotherapy (EBRT) for early prostate cancer (PC). We also examined the prognostic effect of comorbidity by Charlson Comorbidity Index (CCI) and overall performance status by Eastern Clinical Oncology Group (ECOG) score. Methods: A total of 665 men treated between 2008 and 2013 were enrolled from Tampere University Hospital, Finland. Prostate-specific antigen (PSA) tests and hospital records were used to determine the 5-year survival for each aforementioned endpoint using a Kaplan-Meyer estimate. To analyze the impact of the selected prognostic factor, we used a Cox regression model to calculate the corresponding hazard ratio (HR) and 95 % confidence interval (CI). Results: With a median follow-up-time of 7.12 years, the 5-year overall survival (OS) after EBRT was 88.9 % [86.5 %-91.3 %], prostate cancer-specific survival (PCSS) was 97.9 % [96.7 %-99.1%], metastasis-free survival (MFS) 94.8 % [93.0 %-96.6 %] and biochemical recurrence-free survival (BRFS) 88.7 % [86.2 %-91.2 %]. Both CCI (HR = 1.38, [1.25-1.51]) and ECOG score (HR = 1.63, [1.29-2.05]) declined OS, as well as Gleason score and T score (P < 0.05). Gleason score and T grade also associated to worse PCSS, MFS and BRFS. Conclusions: CCI and ECOG score are useful tools in evaluating the overall life expectancy of the patient after EBRT for PC. T-stage and Gleason score remain still the major prognostic factors.
Figure 1
Figure 2
Figure 3
Loading...